In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data

Min Nan Hung, Po Ren Hsueh, Hou Tai Chang, Wen Sen Lee, Ming Yuan Chou, Ing Shen Chen, Jen Hsien Wang, Chen Fu Lin, Jainn Ming Shyr, Wen Chien Ko, Jiunn Jong Wu, Yung Ching Liu, Wen Kuei Huang, Lee Jene Teng, Cheng Yi Liu, Kwen Tay Luh

研究成果: 雜誌貢獻文章

10 引文 斯高帕斯(Scopus)

摘要

We investigated the in vitro activity of various piperacillin and sulbactam combinations against Gram-negative bacterial isolates from Intensive Care Units (ICUs) in Taiwan. Antimicrobial susceptibility testing of 1030 bacterial isolates recovered from ICUs of nine major teaching hospitals was performed using the agar dilution method. Sulbactam was added to piperacillin either at a fixed sulbactam concentration of 4 mg/L and 8 mg/L or at a piperacillin:sulbactam ratio of 2:1 and 4:1. Piperacillin/sulbactam at a ratio of 2:1 or a fixed 8 mg/L concentration of sulbactam had better activities against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Serratia marcescens than other piperacillin/sulbactam formulations. For Pseudomonas aeruginosa, piperacillin/sulbactam (2:1 or 4:1 ratios) had MIC90 values (minimum inhibitory concentration for 90% of the organisms) of 64 mg/L (>90% susceptibility) compared with 64 mg/L for cefoperazone/sulbactam (68% susceptibility) and 128 mg/L for piperacillin/tazobactam (82% susceptibility). For Acinetobacter baumannii, both piperacillin/sulbactam (either 2:1 ratio or a fixed 8 mg/L sulbactam) and cefoperazone/sulbactam were the most potent agents. Adding sulbactam to piperacillin resulted in increased susceptibility rates among piperacillin-resistant P. aeruginosa (53-57% in either 2:1 or 4:1 ratios) and A. baumannii (38-46% in either 2:1 ratio or a fixed 8 mg/L concentration of sulbactam) isolates. Results of susceptibility tests with piperacillin/sulbactam are dependent on the method used. Piperacillin/sulbactam combinations possessed better in vitro activities than piperacillin alone or piperacillin/tazobactam against P. aeruginosa and A. baumannii.

原文英語
頁(從 - 到)145-152
頁數8
期刊International Journal of Antimicrobial Agents
29
發行號2
DOIs
出版狀態已發佈 - 二月 2007
對外發佈Yes

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Microbiology
  • Parasitology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

指紋 深入研究「In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data」主題。共同形成了獨特的指紋。

  • 引用此

    Hung, M. N., Hsueh, P. R., Chang, H. T., Lee, W. S., Chou, M. Y., Chen, I. S., Wang, J. H., Lin, C. F., Shyr, J. M., Ko, W. C., Wu, J. J., Liu, Y. C., Huang, W. K., Teng, L. J., Liu, C. Y., & Luh, K. T. (2007). In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data. International Journal of Antimicrobial Agents, 29(2), 145-152. https://doi.org/10.1016/j.ijantimicag.2006.02.017